Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma.

Saved in:
Bibliographic Details
Title: Phase I trial of pembrolizumab plus vemurafenib and cobimetinib in patients with metastatic melanoma.
Authors: Shaikh SS; Department of Hematology/Oncology, Fox Chase Cancer Center, Philadelphia, PA, United States.; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States., Zang Y; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States., Hanmer J; Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, United States., Wang H; University of Pittsburgh, School of Public Health, Pittsburgh, PA, United States., Lin Y; University of Pittsburgh, School of Public Health, Pittsburgh, PA, United States., Davar D; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States., Zarour HM; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States., Kirkwood JM; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States., Najjar YG; Department of Medicine, Division of Hematology/Oncology, University of Pittsburgh Medical Center Hillman Cancer Centet, Pittsburgh, PA, United States.
Source: Frontiers in oncology [Front Oncol] 2022 Nov 23; Vol. 12, pp. 1022496. Date of Electronic Publication: 2022 Nov 23 (Print Publication: 2022).
Publication Type: Journal Article
Journal Info: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:2234-943X
DOI:10.3389/fonc.2022.1022496